CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

Chart

CRISPR Therapeuticss Options Frenzy: What You Need to Know. Whales with a lot of money to spend have taken a noticeably bearish stance on Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades.If we consider the specifics of each trade it is accurate to state that 7% of the investors opened trades with ish expectations and 84% with bearish.From the overall spotted trades 3 are puts for a total amount of $220010 and 10 calls for a total amount of $579566.Based on t

Today

CRISPR Therapeutics Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial. On Saturday CRSP) shared Phase 1 data from its ongoing clinical trial evaluating CTX310 an investigational in vivo CRISPR/Cas9 gene-editing .ANGPTL3 or Angiopoietin-Like 3 is a protein primarily produced in the liver that plays a major role in regulating blood lipid (fat) levels particularly .A single-course treatment with CTX310 produced dose-dependent durable reductions in circulating ANGPTL

Today

CRSP Posts Narrower-Than-Expected Loss in Q3 Sales Miss Estimates. CRISPR Therapeutics posts a narrower-than-expected Q3 loss trims R&D spend and advances late-stage and next-gen gene-editing programs.

Today

Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged. Crispr stock reversed lower Monday while Intellia stock surged on promising updates for their gene-editing efforts.The post Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged appeared first on Investor'.s Business Daily.

Mon Nov 10, 2025

Why Gene-Editing Giants Crispr And Intellia Just Surged. Crispr stock jumped Monday as Intellia shares surged on promising updates for their gene-editing efforts.The post Why Gene-Editing Giants Crispr And Intellia Just Surged appeared first on Investor'.s Business Daily.

Mon Nov 10, 2025

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics. JUPITER Fla. and DUBLIN Nov. 10 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (ERS'.) the CRISPR licensing company and Dyadic Applied BioSolutions a global biotechnology company producing precision-engineered animal-free proteins and enzymes for diverse commercial applications today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS

Mon Nov 10, 2025

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results. -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine-

Mon Nov 10, 2025

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note. The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16 representing a -2.56% change from its previous close.

Fri Nov 7, 2025

CRISPR Therapeutics Options Trading: A Deep Dive into Market Sentiment. Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics (NASDAQ:CRSP) revealed 9 unusual trades.Delving into the details we found 33% of traders were ish while 44% showed bearish tendencies. Out of all the trades we spotted 4 were puts with a value of $169270 and 5 were calls valued at $277530.Analyzing the Volume and Open Interest in these contrac

Wed Nov 5, 2025

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It. Recently Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Fri Oct 31, 2025